ReviewAntibiotics (Basel, Switzerland)2024
Advances in Development of Novel Therapeutic Strategies against Multi-Drug Resistant
Review in Antibiotics (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 31 citations in OpenAlex.
- Antibiotic Resistance and the Return to a Pre-Antibiotic Era: A Critical Narrative Review of a Global Catastrophe.Biomedicines · 2026Review
- Variable phage susceptibility ofbioRxiv : the preprint server for biology · 2026Article
- Fluorophenylalanine-Containing Dipeptides with Antibiofilm Activity AgainstMolecules (Basel, Switzerland) · 2026Article
- Bibliometric analysis of Pseudomonas aeruginosa vaccine development highlighting research status, evolution, and future opportunities.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Pan-ResistantClinical medicine insights. Case reports · 2026Article
- Factors governing the response ofFrontiers in cellular and infection microbiology · 2026Review
- Ferroptosis and iron-based therapies inVirulence · 2025Review
- Mechanisms of Pseudomonas aeruginosa resistance to type VI secretion system attacks.Nature communications · 2025Article
- Phage Encapsulation and Delivery Technology: A Strategy for Treating Drug-Resistant Pathogenic Microorganisms.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Understanding Drug Permeability inLife (Basel, Switzerland) · 2025Review
- A biofilm-tropiceLife · 2025Article
- In Vitro Antimicrobial Activity of the Novel Antimicrobial Peptide OMN51 Against Multi-Drug-ResistantJournal of clinical medicine · 2025Article
- Antibiotic-ResistantMicroorganisms · 2025Review
- Deciphering Multidrug-ResistantToxics · 2025Review
- Activity of cefiderocol on extensively drug-resistantIranian journal of microbiology · 2025Article
- Pyocins and Beyond: Exploring the World of Bacteriocins in Pseudomonas aeruginosa.Probiotics and antimicrobial proteins · 2025Review
- Unseen Enemy: Mechanisms of Multidrug Antimicrobial Resistance in Gram-Negative ESKAPE Pathogens.Antibiotics (Basel, Switzerland) · 2025Review
- New Exploration of Therapeutic Targets for Radiation Pneumonitis: Comparative Analysis of Molecular Pathways in Radiation-Induced and LPS-Induced Pneumonitis.International journal of medical sciences · 2025Review
- Glutamine potentiates cefoperazone-sulbactam activity againstFrontiers in microbiology · 2025Article
- Transcriptome Analysis Reveals the Mechanism of Y0-C10-HSL on Biofilm Formation and Motility ofPharmaceuticals (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.